Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Teva Pharmaceuticals
Pharma
DEA raises production quota on Takeda's Vyvanse and its generics
With a shortage of ADHD drugs persisting, the DEA has raised production limits on Takeda’s Vyvanse and its generic versions by 24%, the agency said.
Kevin Dunleavy
Sep 4, 2024 3:24pm
FTC targets Novo's Ozempic among 300-plus 'junk' patents
May 1, 2024 7:30am
Teva CEO Richard Francis earns $25.7M thanks to welcome package
Apr 17, 2024 1:00pm
Pfizer ponies up $39M to resolve old pay-for-delay lawsuit
Apr 11, 2024 11:00am
Teva, like Hikma, accuses Amarin of hoarding Vascepa ingredient
Mar 29, 2024 1:10pm
BeiGene, BMS, AZ-FibroGen and more—Fierce Pharma Asia
Mar 1, 2024 8:55am
